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Background: The development of surgical site infection (SSI) following vascular surgery is an important
issue for healthcare providers as it has serious implications for both patient morbidity and mortality.
Methods: Five publications were identiﬁed using the PubMed online database and search terms
‘gentamicin-containing collagen implant’ plus ‘surgical site infection’, ‘wound infection’ and ‘vascular
surgery’.
Results: The reviewed publications demonstrated that prophylactic use of GCCI in conjunction with
standard treatment reduces the SSI rate in patients operated on for femeropopliteal bypass grafting. The
prophylactic use of GCCI may also have a role to play in patients at high-risk of infection (e.g. in those
with co-morbidities such as obesity) and in high-risk procedures (e.g. surgical revision to correct
anastomotic aneurysm or dehiscence). GCCI in conjunction with systemic antibiotics may also be
effective in the treatment of wound infections of the groin following vascular reconstruction.
Conclusion: This review demonstrates that GCCI have a role to play in preventing and treating SSI
following vascular reconstruction when used in conjunction with standard treatment approaches.
Additional randomised, controlled studies are required to further establish the efﬁcacy and cost-
effectiveness of GCCI in vascular surgery.
Crown Copyright  2012 Published by Elsevier Ltd on behalf of Surgical Associates Ltd. All rights
reserved.1. Introduction
The development of surgical site infection (SSI) following
vascular surgery is an important issue for healthcare providers as it
has serious implications for both patient morbidity and mortality.1
Furthermore patients stay in hospital longer increasing length of
stay and incurring signiﬁcant costs for healthcare providers. The
risk of SSI following vascular surgery reported in retrospective
studies has ranged between 4% and 43%.2e10 In prospective studies
the incidence of SSI has ranged between 4% and 25%, being highest
when related to the distal incisions used for femoropopliteal and
femerodistal bypasses.11e13 In a recent analysis of 184 consecutive
patients from several centres in Finland who underwent a range of
vascular surgical procedures the overall rate of SSI was reported as
27%.1
Independent predictors of SSI following vascular surgery have
been established in a number of studies.1,5,8,10,11,14 McAlister and
colleagues identiﬁed post-operative hyperglycaemia as a risk factor2577.
012 Published by Elsevier Ltd on bfor post-operative infection in patients who underwent coronary
artery bypass grafting.14 In 2010 Turtiainen and colleagues identi-
ﬁed a signiﬁcantly higher rate of infection in those patients who
underwent infrainguinal surgery (OR 7.2, 95% CI 2.92e17.65,
p < 0.001) and in those where the angiography puncture site was
within the operative area (OR 2.5, 95% CI 1.13e5.48, p ¼ 0.02).1 This
group also identiﬁed obesity (BMI > 25) as an independent
predictor of SSI (OR 6.1, 95% 2.44e15.16, p < 0.001). This is an
important ﬁnding given the increasing incidence of obesity in the
developed world and therefore in patients undergoing vascular
surgery.
The development of SSI following vascular surgery may result in
exposure of the underlying graft and may also require subsequent
removal of the vascular prosthesis if the infection persists.1 SSI is
therefore associated with a higher risk of subsequent amputation
and also mortality.8,9,15 In an analysis of 1404 patients who
underwent lower limb vein bypass the rate of SSI was 20%.9 The
patients with SSI were at increased risk of limb loss (HR, 1.511; 95%
CI 1.096 to 2.079; p ¼ 0.0116) and had a higher mortality risk (HR,
1.449; 95% CI 1.098 to 1.912; p ¼ 0.0089).9 The cost attributable to
developing an SSI following vascular surgery has been estimated at
V3320 in a study published in 2010.1ehalf of Surgical Associates Ltd. All rights reserved.
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surgical technique is the use of antibiotic prophylaxis.16 However,
long-term administration of systemic antibiotics may lead to a risk
of antibiotic resistance and toxicity.
The emergence of technologies such as resorbable gentamicin-
containing collagen implants (GCCI), which deliver high local
concentrations of gentamicin with corresponding low serum levels
offer both a means of lowering the risk of antibiotic resistance by
reducing the need for long-term administration of systemic anti-
biotics and also avoiding the toxicity of these regimens.17e19 The
use of GCCI also avoids the need for reoperation, as the implant is
fully resorbable unlike polymer polymethylmethacrylate (PMMA)
beads, which require subsequent removal.20 The use of collagen as
a carrier also has a positive effect on wound healing and
haemostasis.18,20
The objective of this article is to review the published clinical
data for prophylactic and therapeutic application of resorbable
GCCI in vascular surgery in order to provide an overview of the
efﬁcacy and safety of GCCI in this indication.
2. Methods
Candidate publications were identiﬁed using the National Institutes of Health
PubMed database for articles published between January 1985 and July 2011. Articles
were identiﬁed using the search terms ‘gentamicin-containing collagen implant’
plus ‘surgical site infection’, ‘wound infection’ and ‘vascular surgery’. Reference lists
of recent review articles were also scanned for additional citations. The literature
search was further supplemented by abstracts from international vascular surgery
congresses, which took place between January 2009 and July 2011. Review publi-
cations were excluded from the analysis. The search identiﬁed ﬁve potential
publications focusing speciﬁcally on the prophylaxis and treatment of SSI in vascular
surgery. These studies concerned the use of one GCCI i.e. Collatamp (EUSA Pharma
[Europe], Oxford, United Kingdom). Collatamp contains gentamicin sulphate at
a rate of 2 mg/cm.2 The collagen in Collatamp is present at 2.8 mg/cm2 and is type I
collagen from a renatured bovine or equine source.
The outcome measures of primary interest were the SSI and wound healing
rates. The level of evidence for each study was graded according to the criteria
developed by Carruthers et al.21
3. Clinical experience
3.1. Prophylaxis
To date there have been ﬁve clinical studies which have focused
on the local application of GCCI in the prophylaxis and treatment of
SSI following vascular surgery (Table 1). One of the studies was of
randomised, controlled design; one was a prospective study with
contemporaneous controls and three studies included a consecu-
tive patient series without contemporaneous controls. One of the
studies was graded as level 1.21 In total these studies represent
experience in n ¼ 109 patients with GCCI in vascular surgery.
One randomised, single centre study (level 1) and a second
prospective study with contemporaneous controls (level 3) have
focused speciﬁcally on the prophylactic use of GCCI following
various vascular procedures.22,23 A recently published randomised
study was carried out in non-diabetic patients with lower limb
ischaemia with indication for femoropopliteal bypass graft.23 Pol-
ytetraﬂuoroethylene (PTFE) supported grafts were used and all
patients were operated on by the same team to ensure consistency.
The use of GCCI (applied in the groin incision) together with
systemic antibiotics was compared to use of systemic antibiotics
alone. At the 30-day follow-up none of the patients in the GCCI
group had developed any signs of SSI compared to ﬁve out of 20 in
the standard treatment group. None of the patients in whom GCCI
were used suffered any local or systemic allergic reactions.
The second of these studies compared use of GCCI to no
adjunctive treatment in a group of patients with renal insufﬁciency
undergoing vascular access for haemodialysis.22 None of thepatients in the GCCI group developed an SSI compared to two out of
20 in the control group. One patient in each group suffered from
a peri-graft-reaction, which disappeared without speciﬁc therapy.
Patients did not experience any systemic side effects following use
of GCCI despite having poor renal function.
Three patient case series (level 5) have been published on the
therapeutic use of GCCI in patients with existing wound infection
following vascular surgery.24e26 Two of these publications also
contained data on the prophylactic use of GCCI.24,253.2. Prophylaxis and treatment
Belz and colleagues analysed the results of 30 patients of mixed
aetiology in which GCCI were used either on a prophylactic or
therapeutic basis (þperi-operative systemic antibiotics) (Table 1).24
The patients ranged in age between 20 and 81 and the male:female
sex ratio was 4:1. The majority of the patients where GCCI were
used therapeutically had exposed synthetic prostheses. GCCI
prophylaxis was used in patients at high-risk of infection including
those undergoing bypass revision, aseptic bypassing and in those
with stage IV arterial occlusion. At least one and a maximum of ﬁve
GCCI were implanted (10 cm  10 cm) at time of operation. Out of
the 26 evaluable patients 22 recovered and four had persistent
infection.
Holdsworth and colleagues subsequently studied the prophy-
lactic and therapeutic use of GCCI in a similar group of patients to
Belz, however, they reported the results for each group separately
(Table 1).25 GCCI prophylaxis was used in patients at high-risk of
infection including those undergoing removal of an infected pros-
thesis and those with persistent lymphatic leak, anastomotic
aneurysm and anastomotic dehiscence. Themajority of the patients
where GCCI were used therapeutically had a graft infection in the
groin area. Between one and three GCCI were inserted on wound
closure.
Wounds were sutured over closed suction drains, which were
removed once the daily ﬂuid collection had reduced to an accept-
ably small amount (3e5 days). GCCI were inserted on a second
occasion if symptoms did not resolve.
Eleven of the 12 patients in whom GCCI were used prophylac-
tically did not grow microorganisms post-surgery and none
developed infective complications on follow-up. One patient died
in hospital. Seven out of the 11 in situ infections and all of the
superﬁcial infections treated with GCCI were cleared. Grafts were
removed in all three of the treatment failures and two of these
patients subsequently lost a leg. One patient who failed treatment
died before the outcome was known. None of the patients treated
successfully had a recurrence of their infection on follow-up (4e42
months).3.3. Treatment
Jørgensen and colleagues analysed the clinical effect of GCCI
(þsystemic antibiotics) in a group of 14 patients with deep but
localised groin infection after vascular reconstruction (Table 1).26
The average age of the patients was 67 years (range 47e86
years). Twelve of the 14 patients had a Szilagyi type III1 infection.
Signs of infection included abscess (n ¼ 10), discharge (n ¼ 3) and
ﬁstula (n ¼ 1). One GCCI (10 cm  10 cm) containing 130 mg
gentamicin was inserted prior to wound closure. Systemic antibi-
otic treatment was started immediately post-surgery with 1.5 g of
IV cefuroxime given three times daily. The systemic treatment was
later changed in ﬁve patients upon culture results. Systemic treat-
ment was continued for three days in four patients; for 10 days in
ﬁve patients and for three months in the remaining ﬁve patients.
Table 1
Overview of GCCI clinical publications in vascular surgery.
Author & evidence grading Product Study design and population Number of subjects and treatment groups Results
Prophylaxis
Horch (1989)22
Level 3
Collatampa Prospective, open, single centre
study with contemporaneous controls
Patients with renal insufﬁciency
undergoing grafts for vascular access
for haemodialysis
n ¼ 40 total patients,
Group I: n ¼ 20 gentamicin-collagen
implant,
Group II: n ¼ 20 control
Wound infection: Group I: 0/20 vs Group II: 2/20
Costa Almeida (2010)23
Level 1
Collatamp
One implant placed
adjacent to prosthesis
Randomised, prospective, single
centre study
Non-diabetic patients with lower limb
ischaemia with indication for
femoropopliteal bypass graft
PTFE supported grafts were used
n ¼ 40 total patients,
Group I: n ¼ 20 gentamicin-collagen
implant þ systemic antibiotics
(piperacilin þ tazobactam),
Group II: n ¼ 20 systemic antibiotics
(piperacilin þ tazobactam)
Wound infection: Group I: 0/20 vs Group II: 5/20
at 30 day follow-up
Prophylaxis & treatment
Belz (1989)24
Level 5
Collatamp Patient case series
Patients undergoing vascular surgery
for a variety of indications
n ¼ 30 patients treated with gentamicin
collagen implant of which n ¼ 26 were
evaluable,
n ¼ 10 GCCI prophylaxis þ systemic
antibiotics,
n ¼ 16 GCCI treatment
Wound healing: 22/26 evaluable patients recovered
and 4/30 had persistent infection.
Holdsworth (1999)25
Level 5
Collatamp Case series report
Patients with infective and potentially
infective complications of vascular
bypass grafting
n ¼ 25 total patients
Prophylaxis (n ¼ 12):
n ¼ 4 at removal of infected prosthesis,
n ¼ 4 for persistent lymphatic leak,
n ¼ 3 anastomotic aneurysm,
n ¼ 1 anastomotic dehiscence.
Treatment (n ¼ 13):
n ¼ 11 in situ for proven graft infection,
n ¼ 2 superﬁcial wound infection over
underlying graft.
In 3 patients GCCI were used with
rifampicin-soaked collagen impregnated
Dacron
Prophylaxis:
Wound infection: 11/12 patients did not grow
microorganisms post-surgery and none developed
infective complications on follow-up. One patient
died in hospital.
Treatment:
Wound infection: 7/11 in situ infections and 2/2
superﬁcial infections were cleared. Grafts were
removed in all 3 of the treatment failures and 2 of
these patients subsequently lost a leg. One patient
died before the outcome was known. None of the
patients treated successfully had a recurrence of
their infection on follow-up (4e42 months).
Treatment
Jørgensen (1991)26
Level 5
Collatamp
One implant was wrapped
around the graft and the
wound closed with suction
drainage placed in contact
with the implant and graft
Patient case series
Patients with localised groin wound graft
infection after vascular reconstruction. All
patients were treated by surgical revision
n ¼ 14 patients treated with gentamicin
collagen implant plus systemic antibiotics
(cefuroxomine 1.5 g tid initially with 5
patients requiring change of antibiotic
on culture result)
Wound infection: Of the 14 patients treated 13
were cured of infection with patent grafts. Of the
12 patients with Szilagyi type III prosthetic
infectionb, 11 were cured
a Also known as Collatamp EG, Collatamp G Cronocol, Duracoll Implant, Garacol, Garacoll, Garacoll Implant, Garamacin Pads, Garamycin, Garamycin Schwamm, Gentacoll, Gentacoll Implant, Gentalyn,
Gentimplant, Sulmycin, Sulmycin Implant E Schwamm, Sulmycin Implant Schwamm
b deep groin infection requiring operative debridement with graft involvement (Szilagyi III).
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ORIGINAL RESEARCHThis group also studied the pharmacokinetic proﬁle of GCCI in the
early post-operative phase in 11 out of the 14 patients.
Of the 14 patients treated with GCCI and systemic antibiotics, 13
were cleared of infection and had patent grafts following surgical
revision. Of the 12 patients with Szilagyi type III prosthetic infec-
tion, 11 were cleared of infection. The wounds in the cleared
patients had healed by the seventh post-operative day without
signs of infection. One of the 13 cleared patients died two months
following surgical revision. Patients were followed up for an
average of 10 months (range 6e15 months) and remained free of
clinical signs of infection and with normal white cell counts. No
adverse events were observed. In particular toxic effects of genta-
micin were not seen even in patients with mild pre-operative
uraemia (serum creatinine > 0.17 mmol/L).
The pharmacokinetic analysis showed a high initial gentamicin
concentration in wound ﬂuid, which exceeded the minimum inhib-
itory concentration (MIC) values for the majority of bacteria causing
graft infection. These MIC values were sustained for 2e3 days.
4. Discussion
This review has demonstrated that prophylactic use of GCCI in
conjunction with standard treatment can reduce the SSI rate in
patients operated on for femeropopliteal bypass grafting. The
prophylactic use of GCCI may also have a role to play in patients at
high-risk of infection (e.g. in those with co-morbidities such as
obesity) and in high-risk procedures such as surgical revision to
correct anastomotic aneurysm or dehiscence. These are important
ﬁndings given the high risk of amputation and also mortality
associated with graft failure.
This review has also demonstrated that GCCI in conjunction
with systemic antibiotics may be effective in the treatment of
wound infections of the groin following vascular reconstruction.
The cure rate even in patients with Szilagyi III infection was high
and sustained. Few adverse side effects were associated with the
prophylactic or therapeutic use of GCCI evenwhen used in patients
with mild renal impairment.
The results of the reviewed studies were consistently positive
across a range of patient types and procedures. However, addi-
tional randomised controlled studies are required to evaluate the
efﬁcacy, safety and cost-effectiveness of GCCI in the prevention
and treatment of SSI following vascular reconstruction. A mul-
ticentre, prospective, randomised, controlled trial focusing on
the prophylactic use of GCCI in vascular groin access procedures
has recently been registered with the EU Clinical Trials
Register.27 Primary outcome measures will include SSI rate,
prosthetic graft infection (classiﬁed according to Szilagyi) at 30
days post-surgery. Secondary endpoints include isolation of
causative bacteria, length of hospital stay, readmission and
reoperation. Safety parameters will include measurement of
creatinine clearance.5. Conclusion
This review demonstrates that GCCI does have a role to play in
preventing and treating SSI following vascular reconstruction when
used in conjunctionwith standard treatment approaches. Additional
randomised, controlled studies are required to further establish the
efﬁcacy and cost-effectiveness of GCCI in vascular surgery.Acknowledgments
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